CONVERT PHARMACEUTICALS
Timeline
28 events since 2017The 2026 accounts are due by 31-07-2027.
2 directors reappointed (director) and (director) · acts as permanent representative · General meeting of 17-09-20268 points ▸
- General meeting of 17-09-2026
- reappointed as director
- reappointed as director
- is in office as director
- is in office as director
- is in office as director
- is in office as director
- acts as permanent representative
- The deed holds 1 more point.
acts as permanent representative reappointed as director · General meeting of 31-07-202610 points ▸
- General meeting of 31-07-2026
- Power of attorney granted to
- Power of attorney granted to
- Power of attorney granted to
- is in office as director
- is in office as director
- is in office as director
- is in office as director
- acts as permanent representative
- reappointed as director
- The deed holds 1 more point.
appointed as directorGeneral meeting of 01-06-20265 points ▸
- General meeting of 01-06-2026
- appointed as director
- Power of attorney granted to
- Power of attorney granted to
- Power of attorney granted to
Registered office moved within LiègeThe registered office moved from Clos Chanmurly 13, 4000 Liège to Silversquare Guillemins - Esplanade Simone Veil 1, 4000 Liège · resigns as director · appointed as director · Board meeting of 01-07-20257 points ▸
- Board meeting of 27-11-2024
- Board meeting of 01-07-2025
- Board meeting of 15-05-2025
- resigns as director
- appointed as director
- General meeting of 02-06-2025
- The registered office moved to Silversquare Guillemins - Esplanade Simone Veil 1, 4000 Liège
Capital increase of €952,497 to €2,222,683The capital rose from €1,270,186 to €2,222,683, with 276,086 new shares · General meeting of 24-06-20254 points ▸
- General meeting of 24-06-2025
- The capital was increased by €952,497
- Capital contribution, €952,497
- Article 5 of the articles of association amended
- The deed holds 8 more points.
Registered office moved within LiègeThe registered office moved from Quai Banning 6 4000 Liège to Clos Chanmurly 13, 4000 Liège · , , and resign · and act as permanent representatives12 points ▸
- The registered office moved to Clos Chanmurly 13, 4000 Liège
- The capital is €1,270,186, divided into 1,667,626 shares
- resigns as director
- acts as permanent representative
- resigns as director
- acts as permanent representative
- resigns as director
- resigns as director
- appointed as director
- appointed as director
- appointed as director
- Discharge granted to )
- The deed holds 7 more points.
1 director appointed, 2 resignations (director) and . (managing director) resign · appointed as director · acts as permanent representative · General meeting of 11-01-20197 points ▸
- General meeting of 11-01-2019
- resigns as director
- appointed as director
- Board meeting of 11-01-2019
- . resigns as managing director
- appointed as managing director
- acts as permanent representative
2 directors appointed, 1 resignation resigns as director · (director) and . (managing director) appointed · acts as permanent representative · General meeting of 02-10-20177 points ▸
- General meeting of 02-10-2017
- resigns as director
- appointed as director
- Board meeting of 02-10-2017
- resigns as managing director
- . appointed as managing director
- acts as permanent representative
Registered office moved from Saint-Gilles to LiègeThe registered office moved from Rue d'Ecosse 28, 1060 Saint-Gilles to Quai Banning 6 4000 Liège · General meeting of 10-08-20172 points ▸
- General meeting of 10-08-2017
- The registered office moved to Quai Banning 6 4000 Liège
Capital increase of €265,626 to €1,270,186The capital rose from €1,004,560 to €1,270,186, with 265,626 new shares6 points ▸
- The capital was increased by €265,626
- Article 5 of the articles of association amended
- Article 13 of the articles of association amended
- Article 15 of the articles of association amended
- Power of attorney granted to
- Power of attorney granted to
- The deed holds 6 more points.
Capital of €1,004,560, 1,402,000 shares3 points ▸
- The capital is €1,004,560, divided into 1,402,000 shares
- Power of attorney granted to
- Power of attorney granted to
IncorporationFounding capital of €504,560, 902,000 shares · Founded by (comparant), (comparant), (comparant) and 2 others · , , , and appointed · published on 28-02-201718 points ▸
- The board has 5 directors
- appointed as director
- appointed as director
- appointed as director
- acts as permanent representative
- appointed as director
- acts as permanent representative
- appointed as director
- appointed as chair of the board
- appointed as managing director
- Founded by
- Founded by
- Founded by
- Founded by
- Founded by
- The founding capital is €504,560, divided into 902,000 shares
- Capital contribution, €154,320
- The capital is €504,560, divided into 902,000 shares
- The deed holds 6 more points.
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
On 24 February 2017, CONVERT PHARMACEUTICALS was incorporated by , and three private individuals, with a starting capital of €504,560.12 In 2017 the registered office moved to Liège.3 The capital was increased 2 times between 2017 and 2025, most recently to €2.2m.45 Today the board has 4 members.6 Total assets went from €1.8m in 2018 to €941,204 in 2025 and headcount from 4.6 full-time equivalents in 2018 to 0.3 in 2023.7